What is Zacks Research’s Estimate for BAX Q1 Earnings?

Baxter International Inc. (NYSE:BAXFree Report) – Zacks Research reduced their Q1 2025 EPS estimates for shares of Baxter International in a research report issued to clients and investors on Thursday, March 13th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will post earnings per share of $0.49 for the quarter, down from their previous estimate of $0.50. The consensus estimate for Baxter International’s current full-year earnings is $2.48 per share. Zacks Research also issued estimates for Baxter International’s Q2 2025 earnings at $0.60 EPS, Q3 2025 earnings at $0.66 EPS, Q1 2026 earnings at $0.52 EPS, Q2 2026 earnings at $0.65 EPS, Q3 2026 earnings at $0.73 EPS, FY2026 earnings at $2.63 EPS and FY2027 earnings at $2.82 EPS.

Several other equities analysts have also commented on the stock. Barclays increased their target price on shares of Baxter International from $39.00 to $41.00 and gave the company an “overweight” rating in a report on Monday, March 10th. Argus raised shares of Baxter International from a “hold” rating to a “buy” rating in a report on Monday, February 24th. JPMorgan Chase & Co. cut their price target on shares of Baxter International from $38.00 to $36.00 and set a “neutral” rating on the stock in a report on Friday, February 21st. The Goldman Sachs Group began coverage on shares of Baxter International in a report on Wednesday, February 26th. They issued a “buy” rating and a $42.00 price target on the stock. Finally, Citigroup cut their price target on shares of Baxter International from $37.00 to $35.00 and set a “neutral” rating on the stock in a report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $38.56.

View Our Latest Report on BAX

Baxter International Price Performance

BAX stock opened at $34.64 on Monday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.09 and a current ratio of 1.43. Baxter International has a 52 week low of $28.34 and a 52 week high of $43.99. The firm’s fifty day moving average is $32.46 and its 200 day moving average is $33.95. The firm has a market cap of $17.72 billion, a P/E ratio of -27.06, a P/E/G ratio of 0.93 and a beta of 0.60.

Baxter International (NYSE:BAXGet Free Report) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $0.58 EPS for the quarter, beating the consensus estimate of $0.52 by $0.06. Baxter International had a negative net margin of 5.05% and a positive return on equity of 16.67%. The company had revenue of $2.75 billion for the quarter, compared to analyst estimates of $2.67 billion.

Institutional Investors Weigh In On Baxter International

Several institutional investors and hedge funds have recently modified their holdings of BAX. CoreFirst Bank & Trust purchased a new stake in shares of Baxter International in the 4th quarter worth about $26,000. Riverview Trust Co lifted its position in shares of Baxter International by 5,488.2% in the 4th quarter. Riverview Trust Co now owns 950 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 933 shares during the period. LRI Investments LLC lifted its position in shares of Baxter International by 60.8% in the 3rd quarter. LRI Investments LLC now owns 1,560 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 590 shares during the period. Bruce G. Allen Investments LLC lifted its position in shares of Baxter International by 247.3% in the 4th quarter. Bruce G. Allen Investments LLC now owns 2,622 shares of the medical instruments supplier’s stock worth $76,000 after purchasing an additional 1,867 shares during the period. Finally, CKW Financial Group lifted its position in Baxter International by 19.3% during the 4th quarter. CKW Financial Group now owns 2,625 shares of the medical instruments supplier’s stock valued at $77,000 after acquiring an additional 425 shares during the period. 90.19% of the stock is owned by hedge funds and other institutional investors.

Baxter International Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Friday, February 28th will be given a $0.17 dividend. The ex-dividend date of this dividend is Friday, February 28th. This represents a $0.68 annualized dividend and a dividend yield of 1.96%. Baxter International’s dividend payout ratio is -53.13%.

Baxter International Company Profile

(Get Free Report)

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.

Further Reading

Earnings History and Estimates for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.